Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$155.29 USD

155.29
1,094,683

+0.46 (0.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $155.34 +0.05 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (29 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Labcorp Stock Gains From Biopharma Business Amid FX Woe

by Zacks Equity Research

LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

by Zacks Equity Research

RVTY's continued focus on innovations and a strong product portfolio raise optimism about the stock.

Here's Why You Should Add Masimo Stock to Your Portfolio Now

by Zacks Equity Research

MASI's R&D activities raise optimism about the stock.

Reasons to Retain Cardinal Health Stock in Your Portfolio Now

by Zacks Equity Research

CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales Rise

by Zacks Equity Research

AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business.

Reasons to Add Baxter International Stock to Your Portfolio Now

by Zacks Equity Research

BAX's robust growth across all regions, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Here's Why You Should Retain Merit Medical Stock in Your Portfolio

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Reasons to Add Avanos Medical Stock in Your Portfolio Now

by Zacks Equity Research

AVNS's strong product line and focus on R&D raise optimism about the stock.

FMS Stock Rides on Diversified Portfolio and Restructuring Initiatives

by Zacks Equity Research

Fresenius Medical Care's diversified portfolio helps to fight competition and maintain market leadership.

Stryker Stock Gains 18.6% YTD: What's Driving its Share Price?

by Zacks Equity Research

Styker's flagship, Mako Total Knee Platform, its strategic acquisitions and a diversified product portfolio raise optimism about the stock.

Reasons to Retain GE HealthCare Stock in Your Portfolio Now

by Zacks Equity Research

GEHC's continued focus on innovations, acquisitions and partnerships raise optimism about the stock.

SYK Stock May Gain From Completion of Vertos Medical Acquisition

by Zacks Equity Research

Stryker completes the acquisition of Vertos Medical to expand its interventional pain management solutions.

Is HealthEquity Stock a Buy Now Amid Strength in HSAs?

by Zacks Equity Research

HQY's strong quarterly results and solid top-line growth raise optimism about the stock.

ITGR Shares Gain on the Divestiture of Its Non-Medical Business Line

by Zacks Equity Research

Integer Holdings announces to divest its Electrochem business to Ultralife for $50 million in cash.

Baxter Shares May Gain on the Launch of Its Latest Vest APX System

by Zacks Equity Research

BAX launches its next-generation airway clearance system, The Vest APX System, for chronic lung conditions.

Is Quest Diagnostics (DGX) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

PDCO Shares Gain Following New Deals to Boost Animal Health Business

by Zacks Equity Research

Patterson Companies announces to invest in two separate businesses to boost its animal health business.

ENTX & OPK Stock May Gain Following Positive PK/PD Research Data

by Zacks Equity Research

Entera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual agonist GLP-1/glucagon peptide.

Here's Why you Should Retain Nevro Stock in Your Portfolio Now

by Zacks Equity Research

Strength in NVRO's Senza Platform and business diversification plans raises optimism about the stock.

NVRO Stock May Gain on the FDA Approval of Its HFX AdaptivAI Platform

by Zacks Equity Research

Nevro announces the FDA approval and limited market release of HFX iQ with HFX AdaptivAI.

Reasons to Retain Veeva Systems Stock in Your Portfolio Now

by Zacks Equity Research

VEEV's robust product portfolio raises optimism about the stock. However, stiff competition and escalating costs are concerning.

Quest Diagnostics Stock Gains From New Offerings, Customer Wins

by Zacks Equity Research

A key driver in Brain Health growth is Quest Diagnostics' Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF tests.

ITGR Shares May Gain on the Completion of Irish Facility Expansions

by Zacks Equity Research

Integer Holdings announces the completion of its Irish facility expansions in Galway and New Ross to support growth.

Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Stryker Shares May Gain on the Completion of the Acquisition of NICO

by Zacks Equity Research

SYK completes the acquisition of NICO to strengthen its portfolio of solutions for tumor resection and the treatment of ICH.